Prelude Capital Management’s Axonics, Inc. Common Stock AXNX Stock Holding History

Prelude Capital Management’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-77,851	Closed	-$5.42M	–	1631
2024 Q3	$5.42M	Buy	77,851 +3,684	+5%	+$253K	0.33%	54
2024 Q2	$4.99M	Buy	74,167 +16,428	+28%	+$1.11M	0.35%	59
2024 Q1	$3.98M	Buy	57,739 +53,414	+1,235%	+$3.6M	0.21%	91
2023 Q4	$269K	Buy	+4,325	New	+$242K	0.02%	784
2023 Q1	–	Sell	-13,249	Closed	-$828K	–	1532
2022 Q4	$828K	Buy	13,249 +4,116	+45%	+$273K	0.04%	422
2022 Q3	$643K	Buy	9,133 +1,584	+21%	+$109K	0.02%	549
2022 Q2	$428K	Buy	+7,549	New	+$414K	0.01%	882
2019 Q2	–	Sell	-10,481	Closed	-$251K	–	2226
2019 Q1	$251K	Buy	+10,481	New	+$190K	0.01%	642

Other funds holding AXNX

TCA

Taconic Capital Advisors New York $212M AUM 100.15% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's AXNX Position: Q4 2024 in Review

Prelude Capital Management sold out of Axonics, Inc. Common Stock (AXNX) in Q4 2024, closing a stake of 77,851 shares — an estimated $5.42M sold.

Prelude Capital Management first reported a position in AXNX in Q1 2019 and held it in 8 quarters. The position peaked at $5.42M in Q3 2024. 2 funds tracked by Wall St. Rank hold AXNX as of Q4 2024.

Prelude Capital Management reported no remaining Axonics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Prelude Capital Management sold 77,851 Axonics, Inc. Common Stock shares in Q4 2024, an estimated $5.42M.
Prelude Capital Management first reported a position in Axonics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Prelude Capital Management's Axonics, Inc. Common Stock position peaked at $5.42M in Q3 2024.
2 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.